Strs Ohio Sells 25,069 Shares of Halozyme Therapeutics, Inc. $HALO

Strs Ohio trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 89.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,930 shares of the biopharmaceutical company’s stock after selling 25,069 shares during the period. Strs Ohio’s holdings in Halozyme Therapeutics were worth $215,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. Covestor Ltd lifted its holdings in Halozyme Therapeutics by 19.3% during the 3rd quarter. Covestor Ltd now owns 2,347 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 379 shares in the last quarter. Scissortail Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter worth $209,000. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at $25,000. Arkadios Wealth Advisors boosted its holdings in Halozyme Therapeutics by 5.1% in the third quarter. Arkadios Wealth Advisors now owns 16,386 shares of the biopharmaceutical company’s stock valued at $1,202,000 after acquiring an additional 797 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC increased its position in Halozyme Therapeutics by 39.8% in the third quarter. NorthCrest Asset Manangement LLC now owns 30,553 shares of the biopharmaceutical company’s stock worth $2,241,000 after purchasing an additional 8,696 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $78.80.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer owned 708,719 shares in the company, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 41,398 shares of company stock worth $2,861,352. Corporate insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $74.45 on Tuesday. The firm’s 50 day moving average price is $68.94 and its two-hundred day moving average price is $68.64. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $79.50. The firm has a market cap of $8.76 billion, a P/E ratio of 15.67, a PEG ratio of 0.31 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the business posted $1.27 earnings per share. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.